Osteogenesis Imperfecta
- PMID: 29285457
- PMCID: PMC5729682
- DOI: 10.4103/ijem.IJEM_220_17
Osteogenesis Imperfecta
Abstract
Osteogenesis imperfecta is a common heritable connective tissue disorder. Nearly ninety percent are due to Type I collagen mutations. Type I-IV are autosomal dominant, and Type VI-XIII are autosomal recessive. They are Graded 1-5 based on severity. Genomic testing is done by collagen analysis from fibroblasts. The mainstay of treatment is bisphosphonate therapy. The prognosis is variable.
Keywords: Bisphosphonate; collagen; osteogenesis imperfecta.
Conflict of interest statement
There are no conflicts of interest.
References
-
- Thakker RV, Whyte MP, Eisman J, Igarashi T, editors. Genetics of Bone Biology and Skeletal Disease. San Diego: Academic Press; 2013.
-
- Lowenstein EJ. Osteogenesis imperfecta in a 3,000-year-old mummy. Childs Nerv Syst. 2009;25:515–6. - PubMed
-
- Kuurila K, Kaitila I, Johansson R, Grénman R. Hearing loss in Finnish adults with osteogenesis imperfecta: A nationwide survey. Ann Otol Rhinol Laryngol. 2002;111:939–46. - PubMed
-
- Steiner RD, Adsit J, Basel D. COL1A1/2-Related Osteogenesis Imperfecta. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(®) [Internet] Seattle (WA): University of Washington, Seattle; 1993. [Last cited 2017 Sep 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1295/ - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
